Related Experiment Videos
Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison
G C Toner1, J D Shapiro, C R Laidlaw
1Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia.
Summary
A lower dose of granulocyte colony-stimulating factor (G-CSF) at 2 microg/kg is as effective as the standard 5 microg/kg dose in preventing neutropenia after chemotherapy. This finding supports cost-effective G-CSF therapy for cancer patients.
Area of Science:
- Oncology
- Hematology
Background:
- Granulocyte colony-stimulating factor (G-CSF) is used to mitigate chemotherapy-induced neutropenia.
- Standard G-CSF dosage is 5 microg/kg daily.
- Reducing G-CSF dose may improve cost-effectiveness.
Purpose of the Study:
- To compare the efficacy of a lower dose (2 microg/kg) of lenograstim (G-CSF) against the standard dose (5 microg/kg).
- To assess if a reduced G-CSF dose maintains protection against neutropenia.
- To evaluate the cost-effectiveness implications of lower-dose G-CSF therapy.
Main Methods:
- Randomized crossover trial design.
- Patients received standard-dose chemotherapy followed by lenograstim (2 or 5 microg/kg daily).
- Dose was switched between cycles for each patient to compare outcomes.
Main Results:
- Both 2 microg/kg and 5 microg/kg lenograstim doses showed minimal neutropenia.
- No significant differences were observed in neutropenia duration, severity, or hospitalization rates.
- The lower dose demonstrated comparable efficacy to the standard dose.
Conclusions:
- Lenograstim at 2 microg/kg daily is as effective as 5 microg/kg for preventing neutropenia post-chemotherapy.
- Lower-dose G-CSF has significant implications for reducing healthcare costs.
- This supports the use of a lower, more cost-effective G-CSF dose.